Revenue scaled to $123.0M with gross margin of 70.9% and operating margin expanding to 9.0% from -32.9% a year earlier, though SG&A at roughly 45% of revenue suggests operating leverage is still only partly developed.
BillionToOne, Inc. (BLLN) annual income statement — 3-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 |
|---|
| Sales/Revenue | 436.87M | 305.11M | 152.58M | 71.73M |
| Revenue Growth % | 71.9% | 99.97% | 112.72% | - |
| Cost of Goods Sold | 124.92M | 96.65M | 71.67M | 54.42M |
| COGS % of Revenue | - | 31.68% | 46.97% | 75.87% |
| Gross Profit | 311.95M | 208.46M | 80.92M | 17.31M |
| Gross Margin % | 71.41% | 68.32% | 53.03% | 24.13% |
| Gross Profit Growth % | - | 157.63% | 367.5% | - |
| Operating Expenses | 267.26M | 192.44M | 128.06M | 86.8M |
| OpEx % of Revenue | - | 63.07% | 83.93% | 121.02% |
| Selling, General & Admin | 200.79M | 143.05M | 91.47M | 64.39M |
| SG&A % of Revenue | - | 46.88% | 59.94% | 89.77% |
| Research & Development | 66.47M | 49.38M | 36.6M | 22.41M |
| R&D % of Revenue | - | 16.19% | 23.98% | 31.25% |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| Operating Income | 44.69M | 16.02M | -47.15M | -69.5M |
| Operating Margin % | 10.23% | 5.25% | -30.9% | -96.89% |
| Operating Income Growth % | - | 133.99% | 32.16% | - |
| EBITDA | 60.41M | 27.93M | -35.46M | -63.03M |
| EBITDA Margin % | 13.83% | 9.15% | -23.24% | -87.88% |
| EBITDA Growth % | 916.88% | 178.77% | 43.75% | - |
| D&A (Non-Cash Add-back) | 9.35M | 11.91M | 11.69M | 6.46M |
| EBIT | 49.74M | 7.85M | -39.16M | -79.4M |
| Net Interest Income | 17.48M | 7.66M | 3.43M | 184K |
| Interest Income | 17.51M | 7.75M | 5.82M | 3.46M |
| Interest Expense | 27K | 95K | 2.39M | 3.27M |
| Other Income/Expense | 5.02M | -8.26M | 5.61M | -13.18M |
| Pretax Income | 49.72M | 7.76M | -41.54M | -82.67M |
| Pretax Margin % | 11.38% | 2.54% | -27.23% | -115.26% |
| Income Tax | 324K | 305K | 29K | 9K |
| Effective Tax Rate % | 0.65% | 3.93% | -0.07% | -0.01% |
| Net Income | 49.39M | 7.45M | -41.57M | -82.68M |
| Net Margin % | 11.31% | 2.44% | -27.24% | -115.27% |
| Net Income Growth % | 447.73% | 117.93% | 49.72% | - |
| Net Income (Continuing) | 49.39M | 7.45M | -41.57M | -82.68M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.92 | 0.14 | -4.12 | -1.85 |
| EPS Growth % | 382.37% | 103.4% | -122.7% | - |
| EPS (Basic) | - | 0.18 | -4.12 | -1.85 |
| Diluted Shares Outstanding | 53.73M | 21.23M | 10.08M | 44.72M |
| Basic Shares Outstanding | 47.27M | 15.88M | 10.08M | 44.72M |
| Dividend Payout Ratio | - | - | - | - |
Quick answers to the most common questions about buying BLLN stock.
For fiscal year 2025, BillionToOne, Inc. (BLLN) reported total revenue of $305.1M. This represents a 325.4% increase compared to $71.7M in 2023.
BillionToOne, Inc. (BLLN) is profitable, generating $7.5M in net income for the fiscal year ending 2025 with a net profit margin of 2.4%.
BillionToOne, Inc. (BLLN) reported an operating income of $16.0M, resulting in an operating profit margin of 5.3%. This margin reflects the operational efficiency of the business before interest and taxes.
BillionToOne, Inc. (BLLN) generated $208.5M in gross profit for the year, representing a gross profit margin of 68.3%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Thin margins versus growth
Metrics are mathematically derived from official filings.
Revenue Growth Re-Accelerated Through Latest Quarter
Based on the reported income statement, BLLN's quarterly revenue rose from $45.1M in 2024Q4 to $123.0M in 2026Q3, with year-over-year growth of 47.2% in the latest quarter after exceeding 110% in late 2025, suggesting the trajectory is decelerating from a low base but still strong.
The sequential climb across ten quarters indicates sustained commercial adoption rather than a single step change, though the year-over-year rate in 2026Q3 has compressed from the 113% to 117% range seen in late 2025. This compression is consistent with base-effect normalization and warrants monitoring of whether sequential dollar additions hold up as the comparison base grows larger. Investors should assess whether the growth remains volume-driven rather than reliant on pricing, since the reported figures do not separate these drivers.
Gross Margin Stable Near Seventy Percent
As reported in the income statement, BLLN's gross margin moved from 51.2% in 2024Q2 to 70.9% in 2026Q3, holding within a 70% to 73% band over the last five quarters and pointing to durable unit economics.
The recent stability of gross margin around 70% suggests the cost of revenue is scaling more slowly than sales, which is consistent with a diagnostic product whose incremental testing costs are relatively low. Peer comparison shows Illumina and CareDx at roughly 67% to 68% gross margin, placing BLLN in a comparable range rather than as a clear pricing-power outlier. The sustainability of this level depends on test mix and reimbursement dynamics, which the supplied data does not disclose.
Operating Leverage Emerging But Still Thin
Based on reported figures, BLLN's operating margin improved from negative 32.9% in 2024Q3 to 9.0% in 2026Q3, yet SG&A consumed about 45% of revenue in the latest quarter, indicating operating leverage is only partly developed.
Operating income has turned positive in recent quarters while SG&A has grown in absolute terms, which suggests the company is beginning to scale overhead more efficiently than gross profit. However, SG&A remains close to 45% of revenue, leaving limited room for error if growth decelerates. The next several quarters will show whether SG&A growth lags revenue growth enough to lift operating margin meaningfully above the current single-digit level.
Net Income Trails Operating Profit Consistently
According to reported financials, BLLN's latest net margin of 14.1% exceeded its operating margin of 9.0%, but earlier quarters show net income swinging sharply versus operating income, which warrants a closer look at non-operating items and tax effects.
The gap between operating and net income in recent quarters appears to reflect non-operating items or tax benefits rather than core operating performance, since net margin exceeded operating margin in 2026Q3. Stock-based compensation rose to $9.7M in the latest quarter, a meaningful share of operating income, which may be masking the underlying cash economics of the business. Investors should separate recurring operating earnings from one-time or non-cash items before extrapolating the latest EPS of $0.32.
Growth Durability and Margin Conversion Risks
The strongest bear case rests on BLLN's 2026Q3 operating margin of 9.0% against 47.2% revenue growth, as the spread between top-line expansion and bottom-line conversion may not persist if growth moderates from its base effect.
A skeptic would argue that the EPS beat of $0.32 against a $0.31 consensus is narrow and does not yet establish an earnings inflection, particularly with ROE near 2.3% in the supplied context. If revenue growth decelerates toward the peer range while SG&A stays near 45% of sales, operating margin could stall well below the level implied by the growth trajectory. Investors should treat the raised guidance tone as directional rather than quantified, given that no explicit forward targets are disclosed in the supplied data.